DXCM — DexCom, Inc. stock price, charts and financials

QT70DexCom, Inc.

DexCom, Inc. (NASDAQ: DXCM) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
87.65
+2.90+3.42%
OverviewShort InterestFilings
DXCMQT70DexCom, Inc.·NASDAQ
87.65+3.42%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RMD+3.85%$220.10PHG+0.77%$26.93EW+2.59%$92.04ZBH+1.28%$97.78BSX+2.33%$50.46PEN+0.40%$325.97SNN-0.05%$30.09ALGN+1.37%$176.04
Snapshot
IndexS&P 500, NDXP/E32.72EPS (ttm)2.59Insider Own0.82%Shs Outstand377.36MPerf Week1.56%
Market Cap31.98BForward P/E27.22EPS next Y3.11Insider Trans-3.45%Shs Float376.05MPerf Month16.06%
Enterprise Value32.27BPEG0.43EPS next Q0.67Inst Own94.03%Short Float4.96%Perf Quarter39.14%
Income981.83MP/S6.44EPS this Y5.05%Inst Trans-Short Ratio3.26Perf Half Y21.26%
Sales4.97BP/B12.40EPS next Y17.15%ROA15.49%Short Interest18.65MPerf YTD27.69%
Book/sh-P/C18.60EPS next 5Y17.42%ROE36.19%52W High90.86 -3.53%Perf Year10.93%
Cash/sh-P/FCF22.76EPS past 3/5Y37.73% 10.48%ROIC21.60%52W Low55.96 56.63%Perf 3Y-31.55%
Dividend Est.-EV/EBITDA20.70Sales past 3/5Y17.01% 19.33%Gross Margin62.47%Volatility3.34% 3.60%Perf 5Y-34.24%
Dividend TTM-EV/Sales6.50EPS Y/Y TTM78.17%Oper. Margin22.92%ATR (14)3.09Perf 10Y278.52%
Dividend Ex-Date-Quick Ratio1.43Sales Y/Y TTM23.21%Profit Margin20.12%RSI (14)64.35Recom2.21
Dividend Gr. 3/5Y-Current Ratio1.73EPS Q/Q45.83%SMA209.51%Beta1.38Target Price89.71
Payout0.00%Debt/Eq0.53Sales Q/Q13.05%SMA5013.80%Rel Volume0.80Prev Close84.75
Employees11,100LT Debt/Eq0.50EarningsOct 29SMA20024.26%Avg Volume5.75MPrice87.65
IPO DateApr 14, 2005Option/ShortYes / YesEPS/Sales Surpr.14.75% 1.40%Net Debt/EBITDA0.19Volume4,580,583Change3.42%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedArgus ResearchBuy$86 → $96
Aug-03-26ReiteratedCanaccord GenuityBuy$82 → $90
Jul-31-26ReiteratedRaymond JamesStrong Buy$91 → $94
Jul-31-26ReiteratedRobert W. Baird$80 → $105
Jul-31-26ReiteratedStifel NicolausBuy$90 → $95
Jul-31-26ReiteratedRBC CapitalOutperform$85 → $90
Jul-31-26ReiteratedPiper SandlerOverweight$88 → $95
Jul-31-26ReiteratedBTIGBuy$105 → $90
Jul-31-26ReiteratedTruist SecuritiesBuy$87 → $93
Jul-28-26ResumedUBSBuy$95 → $96
Latest News
Aug-05-26
Aug-05-2607:05PM
Wednesday's session: top gainers and losers in the S&P500 indexChartMill
Aug-03-26
Aug-03-2610:36AM
DexCom (DXCM) Recently Broke Out Above the 20-Day Moving Averagezacks.com
10:31AM
Best Health & Fitness Stocks for Investors Amid Wellness Boomzacks.com
10:16AM
DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue?zacks.com
07:16AM
DexCom: Still A Cautious Buy Following Earningsseekingalpha.com
Jul-31-26
Jul-31-2602:42PM
DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Risezacks.com
12:04AM
DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Signal Robust Momentumgurufocus.com
Jul-30-26
Jul-30-2611:04PM
DexCom Q2 Earnings Call HighlightsYahoo
10:03PM
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcriptseekingalpha.com
06:26PM
DexCom (DXCM) Q2 Earnings and Revenues Top Estimateszacks.com
04:32PM
Dexcom raises annual revenue forecast on strong demand for glucose monitorsreuters.com
04:02PM
Dexcom Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-29-26
Jul-29-2604:34PM
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Holdfool.com
11:56AM
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?zacks.com
09:12AM
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com
Company

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Ownership
Total institutional ownership94.03%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,9694,6624,033——————
Cost of Goods Sold Incl. D&A1,8651,8601,595——————
Gross Profit3,1042,8022,438——————
Selling, General and Administrative Excl. Other1,3621,2911,286——————
Research and Development604599552——————
Other Operating Expense
000——————
Operating Income1,139912600——————
Interest Expense151819——————
Unusual Expense
—————————
Non-Operating Income (Expense)156195128——————
Net Income Before Taxes1,2811,088709——————
Income Taxes280252133——————
Consolidated Net Income1,000836576——————
Net Income From Continuing Operations1,000836576——————
Net Income1,000836576——————
EPS (Recurring)2.592.141.46——————
EPS (Basic, Before Extraordinaries)2.592.141.46——————
EPS (Diluted)2.532.091.42——————
EBITDA1,5601,359946——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio34.6431.7654.77——————
Price To Sales Ratio6.775.557.81——————
Gross Margin62.4760.1060.45——————
Operating Margin22.9219.5614.88——————
Net Margin20.1217.9314.28——————
Shares Outstanding384390405——————
Market Capitalization33,65825,88431,497——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$94.73$83.46$72.19$60.91$49.64● Close Price0.00M1.06M2.13M3.19M4.25MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FOLETTA MARK GDirectorAug 03 '26Sale85.322,000170,64048,852Aug 04
FOLETTA MARK GDirectorJul 31 '26Sale80.002,000160,00050,852Aug 04
SAYER KEVIN RExecutive ChairJul 20 '26Sale76.3226,7562,041,999328,970Jul 21
Brown Michael JonEVP Chief Legal Compliance OffJul 15 '26Sale74.421,700126,514104,653Jul 16
SAYER KEVIN RExecutive ChairJul 06 '26Sale72.0026,7561,926,432355,726Jul 07
FOLETTA MARK GDirectorJun 15 '26Sale74.134,000296,54052,852Jun 17
Brown Michael JonEVP Chief Legal Compliance OffJun 15 '26Sale75.551,700128,435106,353Jun 17
Coleman JonEVP, Chief Commercial OfficerJun 04 '26Sale74.134,911364,05295,450Jun 05
Coleman JonEVP, Chief Commercial OfficerJun 03 '26Sale73.004,912358,576100,361Jun 05
SAYER KEVIN RExecutive ChairMay 21 '26Sale72.0026,7591,926,648382,482May 26
Brown Michael JonEVP, Chief Legal OfficerMay 15 '26Sale59.911,700101,847109,504May 19
Heller Bridgette PDirectorMay 12 '26Sale60.011,01260,73025,007May 14
Brown Michael JonEVP, Chief Legal OfficerApr 15 '26Sale63.041,700107,168111,204Apr 16
Brown Michael JonEVP, Chief Legal OfficerMar 16 '26Sale64.851,700110,245112,904Mar 18
Heller Bridgette PDirectorFeb 12 '26Sale68.011,01268,82626,019Feb 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.